PepTrackevidence-graded reference
KPV
fig.1 — stylized molecular motif
Immune / gut

KPV

Lys-Pro-Val · alpha-MSH C-terminal fragment

Rising 'gut-healing / anti-inflammatory' peptide; the 'K' in the trending KLOW stack; high regulatory salience (July 2026 PCAC).

Evidence
Danimal-only
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Immune / gut
Route
Subcutaneous · Oral · Topical
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
SC ~200-500 mcg/day; oral 250-500 mcg 2x/day (gut-local); topical ~1 mg (vendor '7.5 mg' is a ~7x outlier)
Titration
4-6 wk cycles (community)
Reconstitution — illustrative, not a recommendation
5 mg vial + 2 mL BAC = 2.5 mg/mL; 250 mcg = 10 U, 500 mcg = 20 U on U-100.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. Vendor 'excellent safety / 20+ yrs research' claims contradict FDA (no human data).
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 ~22 Apr 2026
PCAC review
2026-07-23 (FDA-evaluated uses: wound healing, obesity/osteoporosis - NOT the gut use driving demand)
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Animal/in-vitro only (PepT1 uptake, NF-kB inhibition); NO human RCTs, no human PK, no FDA approval. FDA: no human exposure data identified.

04Safety
Contraindications
  • Pregnancy/breastfeedinghard stop
  • Active/history of cancer (precautionary)
  • Active autoimmune disease / immunosuppression (uncharacterized)
Key interactions
  • Immunosuppressants/biologics (theoretical additive immunomodulation)
  • Chemotherapy (uncharacterized)
Serious signals
  • Zero human safety/efficacy data
  • RUO identity/purity/immunogenicity risk
Monitoring
None validated.
05Sources
1FDA PCAC docket FDA-2025-N-6895
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium
← All peptides
Immune / gut

KPV

Lys-Pro-Val · alpha-MSH C-terminal fragment

Rising 'gut-healing / anti-inflammatory' peptide; the 'K' in the trending KLOW stack; high regulatory salience (July 2026 PCAC).

Evidence
D
animal-only
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous · Oral · Topical
Community / anecdotal
Demand
—
honorable mention
WADA
Not listed
sport-legal
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

SC ~200-500 mcg/day; oral 250-500 mcg 2x/day (gut-local); topical ~1 mg (vendor '7.5 mg' is a ~7x outlier)

Worked reconstitution example

5 mg vial + 2 mL BAC = 2.5 mg/mL; 250 mcg = 10 U, 500 mcg = 20 U on U-100.

Titration

4-6 wk cycles (community)

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Removal != legal/approved. Vendor 'excellent safety / 20+ yrs research' claims contradict FDA (no human data).
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 ~22 Apr 2026
PCAC review2026-07-23 (FDA-evaluated uses: wound healing, obesity/osteoporosis - NOT the gut use driving demand)
WADANot listed
03

Evidence — the honest read

Danimal-only

Animal/in-vitro only (PepT1 uptake, NF-kB inhibition); NO human RCTs, no human PK, no FDA approval. FDA: no human exposure data identified.

04

Safety

Contraindications
  • Pregnancy/breastfeedinghard stop
  • Active/history of cancer (precautionary)
  • Active autoimmune disease / immunosuppression (uncharacterized)
Key interactions
  • Immunosuppressants/biologics (theoretical additive immunomodulation)
  • Chemotherapy (uncharacterized)
Serious signals
  • Zero human safety/efficacy data
  • RUO identity/purity/immunogenicity risk
Monitoring

None validated.

05

Sources

01FDA PCAC docket FDA-2025-N-6895
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: medium